Major pharmaceutical companies are committing billions of dollars to expand manufacturing and research capacity in the United States.
Reuters reported that companies are responding to tariff risk, supply-chain concerns and pressure to localize production. The investment wave could increase domestic capacity but may also reshape costs and sourcing strategies across the global drug industry.
